Biofrontera Inc
NASDAQ:BFRI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Biofrontera Inc
NASDAQ:BFRI
|
US |
|
Mirion Technologies Inc
NYSE:MIR
|
US |
Biofrontera Inc
Biofrontera Inc. is a dermatology company that sells prescription products and device systems used by skin doctors, mainly for treating actinic keratosis, a common sun-related precancerous skin condition. Its main product is Ameluz, a topical drug used with a special red-light lamp in photodynamic therapy, along with the light device and related accessories that doctors use in treatment rooms. The company makes money by selling these products through the medical channel to dermatologists and other skin-care specialists. Doctors buy the drug, the lamp system, and the supporting supplies, while Biofrontera also earns recurring sales from repeat treatment use and replacement consumables tied to the therapy workflow. What makes Biofrontera’s business different is that it sits between a drug company and a medical device company. It does not just sell a cream or just sell hardware; it sells a treatment system that has to work together in the clinic. That gives the company a niche role in dermatology, where adoption depends on doctor familiarity, treatment protocols, and reimbursement for office-based care.
Biofrontera Inc. is a dermatology company that sells prescription products and device systems used by skin doctors, mainly for treating actinic keratosis, a common sun-related precancerous skin condition. Its main product is Ameluz, a topical drug used with a special red-light lamp in photodynamic therapy, along with the light device and related accessories that doctors use in treatment rooms.
The company makes money by selling these products through the medical channel to dermatologists and other skin-care specialists. Doctors buy the drug, the lamp system, and the supporting supplies, while Biofrontera also earns recurring sales from repeat treatment use and replacement consumables tied to the therapy workflow.
What makes Biofrontera’s business different is that it sits between a drug company and a medical device company. It does not just sell a cream or just sell hardware; it sells a treatment system that has to work together in the clinic. That gives the company a niche role in dermatology, where adoption depends on doctor familiarity, treatment protocols, and reimbursement for office-based care.
Revenue: Biofrontera reported first-quarter product revenue of $10.1 million, up 17% year over year, driven by 16% Ameluz unit growth and a pricing increase implemented in late 2025.
Margins: Gross margin expanded to about 80% from about 62% a year ago, helped by the new earnout structure after the strategic transaction with Biofrontera AG.
Cash Burn: Cash used in operations was just $70,000, a sharp improvement from $4.1 million in Q1 2025, and management said this keeps the company on track for cash flow breakeven this year.
Pipeline: The company highlighted progress in superficial basal cell carcinoma, actinic keratosis on the extremities/neck/trunk, and acne, with an FDA decision on sBCC due September 28, 2026 and an sNDA filing for expanded AK use planned for Q3 2026.
Launch Readiness: Management said it is ready to launch the sBCC indication quickly if approved, with commercial rollout beginning around the approval window and accelerating into Q1 next year.
Liquidity: The company ended the quarter with $6.3 million in cash and reiterated that it may use revenue growth, a $1 million Xepi milestone, and potentially a working capital line if needed.
Operations: The commercial team said execution improved through lower turnover, more in-person selling, AI-assisted targeting, and the rollout of an inside sales pilot that is already contributing results.
